BROWSE·page 149 of 311

Browse EX-10 agreements

3,723 matching material contract exhibits.


EX-10.1

Jaguar Health, Inc.

FIRST AMENDMENT TO MANUFACTURING AND SUPPLY AGREEMENT

THIS FIRST AMENDMENT TO MANUFACTURING AND SUPPLY AGREEMENT (this “First Amendment”) is dated as of the date of the last signature below with an effective date of January 12, 2026 (the “Effective Date”), by and among Napo Pharmaceuticals, Inc., a company incorporated under the laws of Delaware (“Napo”), Jaguar Health, Inc. d/b/a Jaguar Animal Health, a company incorporated under the laws of Delaware (“Jaguar”), and Woodward Specialty LLC, a limited liability company organized under the laws of Puerto Rico (“Woodward”). Napo and Woodward are each referred to herein, individually, as a “Party” and, together, as the “Parties.”

R E C I T A L S

A. Napo and Woodward are parties to that certain Manufacturing and Supply Agreement, dated as of January 12, 2026 (the “Supply Agreement”).

B. Pursuant to Section 3.1.1 of the Supply Agreement, title to the Effective Date Product Inventory passed to Woodward as of January 12, 2026, in the State of Tennessee.

EX-10.1·8-K·CIK 1585608·ACC 0001193125-26-281969·Filed Jun 25, 2026, 09:15 ET

EX-10.3

MILESTONE SCIENTIFIC INC.

As of June 19, 2026

 

Benedetta Casamento

346 Hillcrest Road

Englewood, NJ 07631

 

Dear Benedetta:

 

On behalf of the Board of Directors of Milestone Scientific Inc. (the “Company”), I am pleased to confirm your appointment as Executive Chairman (or if you prefer, Executive Chairwoman or Executive Chair) of the Board of Directors, effective June 19, 2026 (the “Effective Date”).

 

  1. Position; Duties. The Company hereby offers you employment as Executive Chairman of the Board of Directors (the “Board”) of the Company, with an annual salary as described in the Employment Offer Summary attached to this letter. By acceptance of this offer, you agree to perform the duties and services outlined in the Employment Offer Summary attached hereto, and such other duties and services as are customary for an executive chairman of a company such as the Company and other duties and services as the Board may reasonably request commensurate with your position as Executive Chairman and (a) to devote such business time and attention to the business and affairs of the Company and to

EX-10.3·8-K·CIK 855683·ACC 0001493152-26-030044·Filed Jun 25, 2026, 09:00 ET

EX-10.1

MILESTONE SCIENTIFIC INC.

Execution Version (2)

 

Agreement

With respect to

Compensation and Other Arrangements

 

THIS AGREEMENT, made as of April 1, 2026 (the “Effective Date”), is made by and among Leonard Osser, residing at 32 Camlet Court, Roseland, New Jersey 07068 (“Executive”), U.S. Asian Consulting Group, LLC, a Delaware limited liability company (“U.S. Asian”), and Milestone Scientific, Inc., a Delaware corporation having its office at 425 Eagle Rock Avenue, Suite 403, Roseland, New Jersey 07068 (the “Company” and, together with Executive and U.S Asian, each “Party” and collectively, the “Parties”).

 

RECITALS

A. Executive is a principal and together with his wife the sole members of U.S. Asian; and

 

B. The Company and Executive entered into an Employment Agreement dated July 11, 2017 (the “Employment Agreement”), and the Company and U.S. Asian entered into a Consulting Agreement dated July 10, 2017 (the “Consulting Agreement”); and

EX-10.1·8-K·CIK 855683·ACC 0001493152-26-030044·Filed Jun 25, 2026, 09:00 ET

EX-10.2

MILESTONE SCIENTIFIC INC.

FORM OF LOCK-UP AGREEMENT

 

June 19, 2026

 

Milestone Scientific Inc.

425 Eagle Rock Road, Ste 403

Roseland, NJ 07068

 

 

Re:

Amendment to Services Agreement effective as of April 1, 2026 with Milestone Scientific, Inc.

 

Ladies and Gentlemen:

 

The undersigned acknowledges that Milestone Scientific, Inc. (the “Company”) and the undersigned are substantially contemporaneously herewith amending certain service agreements between the Company and the undersigned or an affiliate of the undersigned (the “Service Agreements”).

EX-10.2·8-K·CIK 855683·ACC 0001493152-26-030044·Filed Jun 25, 2026, 09:00 ET

EXHIBIT 10.1

SUI Group Holdings Ltd.


Exhibit 10.1

Execution Version

AMENDED AND RESTATED

DIGITAL CURRENCY LOAN AGREEMENT

 

This Amended and Restated Digital Currency Loan Agreement (this “Agreement”) is made on this 19th  day of June, 2026 (the “Effective Date”), by and between BlueFin Labs Inc., a company organized and existing under the laws of Panama (together with its Affiliates, the “Borrower”), and Sui Group Holdings Limited (the “Lender”), a corporation organized and existing under Minnesota law with an address of 1907 Wayzata Blvd, #205, Wayzata, Minnesota. The Lender and the Borrower are sometimes referred to herein as “Party” individually and together as “Parties”.

 

RECITALS

 

WHEREAS, the Parties entered into that certain Digital Currency Loan Agreement (the “Initial Agreement”), dated as of September 30, 2025 (“Initial Effective Date”);

 

WHEREAS, on the Initial Effective Date, the Lender delivered to BlueFin Labs Inc. (Panama) 2,000,000 (two million) SUI tokens (the “Initial Loaned Digital Currency”) on the terms and conditions set forth in the Initial Agreement;

EX-10.1·8-K·CIK 1425355·ACC 0001140361-26-026330·Filed Jun 25, 2026, 08:54 ET

LEASE AGREEMENT BETWEEN

FGHP TRIPLEX, LLC

A DELAWARE LIMITED LIABILITY COMPANY

AS LANDLORD, AND

UNUSUAL MACHINES, INC.,

A NEVADA CORPORATION

AS TENANT

DATED June 24, 2026

 

 

 

 

 

TABLE OF CONTENTS

 

 

 

Page

 

 

 

 

Lease Grant

1

 

 

 

 

Term and Construction and Acceptance of Premises

1

(a)

Lease Term

1

(b)

Landlord's Construction Obligation

1

(c)

Proportionate Share

1

Rent

1

(a)

Basic Rent

1

(b)

Payment

1

(c)

Operating Costs

2

Delinquent Payment; Handling Charges

3

 

 

 

 

 

Security Deposit

3

Landlord's Maintenance Obligations

3

(a)

Landlord's Obligations

3

(b)

Landlord's Right to Perform Tenant's Obligations

3

Improvements; Alterations; Repairs; Tenant's Maintenance; and Utilities

4

(a)

Improvements; Alterations

4

(b)

Repairs; Maintenance

4

(c)

Performance of Works

4

(d)

Mechanic's Liens

4

(e)

Utilities

5

Use

5

Assignment and Subletting

5

(a)

Transfers

5

(b)

Requests for Consent

5

(c)

Consent Standards

5

(d)

EX-10.1·8-K·CIK 1956955·ACC 0001683168-26-005100·Filed Jun 25, 2026, 08:40 ET

EX-10.1

Planet Fitness, Inc.

Document

Ex. 10.1

June 18, 2026

Sudhanshu Priyadarshi

Via Electronic Delivery

Dear Sudhanshu,

We are delighted to offer you the opportunity to join the Planet Fitness team! We believe your skills, knowledge and experience are the right combination for success in the role of Chief Financial Officer and President, International. This letter will confirm our offer of employment to you with Pla-Fit Franchise, LLC (the “Company”), under the terms and conditions that follow:

1. POSITION AND DUTIES:

On June 25, 2026 (the “Start Date”), you will be employed by the Company, on a full-time basis, in the role of Chief Financial Officer and President, International. You agree to perform the duties of your position and such other duties as may reasonably be assigned to you. You also agree to comply at all times with the Company’s policies, practices and procedures, including, but not limited to, the Planet Fitness Code of Ethics.

2. COMPENSATION AND BENEFITS:

EX-10.1·8-K·CIK 1637207·ACC 0001637207-26-000038·Filed Jun 25, 2026, 08:31 ET

EXHIBIT 10.3

SELLAS Life Sciences Group, Inc.

June 24, 2026

 

Dragan Cicic, M.D.

c/o SELLAS Life Sciences Group, Inc.

7 Times Square, Suite 2503

New York, NY 10036

 

Re: Amended and Restated Severance and Change of Control Letter Agreement

 

Dear Dragan:

 

This Amended and Restated Severance and Change of Control Letter Agreement (this “Agreement”) amends and restates in its entirety (i) that certain Change of Control Severance Agreement (the “COC Severance Agreement”), dated December 14, 2021, as amended on March 4, 2025, by and between you and SELLAS Life Sciences Group, Inc. (the “Company”) and (ii) that certain Severance Agreement (the “Severance Agreement”), dated January 22, 2024, by and between you and the Company. Effective as of the date hereof, the COC Severance Agreement and the Severance Agreement shall be of no further force or effect.

 

This Agreement sets forth the severance benefits that shall be provided to you in the event of certain terminations of your employment with the Company (or its successor in a Change of Control (as hereinafter defined)), on the terms and conditions set forth herein.

EX-10.3·8-K·CIK 1390478·ACC 0001104659-26-077556·Filed Jun 25, 2026, 08:30 ET

EXHIBIT 10.2

SELLAS Life Sciences Group, Inc.

June 24, 2026

 

John Burns

c/o SELLAS Life Sciences Group, Inc.

7 Times Square, Suite 2503

New York, NY 10036

 

Re: Amended and Restated Severance and Change of Control Letter Agreement

 

Dear John:

 

This Amended and Restated Severance and Change of Control Letter Agreement (this “Agreement”) amends and restates in its entirety (i) that certain Change of Control Severance Agreement (the “COC Severance Agreement”), dated December 14, 2021, as amended on March 4, 2025, by and between you and SELLAS Life Sciences Group, Inc. (the “Company”) and (ii) the non-change of control severance benefits (such severance benefits, the “Non-COC Severance Benefits”) set forth in that certain Employment Agreement (the “Employment Agreement”), dated January 11, 2018, by and between you and the Company. Effective as of the date hereof, the COC Severance Agreement and the Non-COC Severance Benefits shall be of no further force or effect.

EX-10.2·8-K·CIK 1390478·ACC 0001104659-26-077556·Filed Jun 25, 2026, 08:30 ET

EXHIBIT 10.1

SELLAS Life Sciences Group, Inc.

June 24, 2026

 

Angelos M. Stergiou, M.D., Sc.D. h.c.

c/o SELLAS Life Sciences Group, Inc.

7 Times Square, Suite 2503

New York, NY 10036

 

Re: Amendment to Employment Agreement

 

Dear Angelos:

 

This amendment (this “Amendment”) will serve to implement certain changes to your Employment Agreement with SELLAS Life Sciences Group, Inc. (the “Company”), effective July 1, 2019 (the “Agreement”). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Agreement.

 

1.

Severance. The Agreement is hereby amended by replacing Section 4(J) of the Agreement with the following:

EX-10.1·8-K·CIK 1390478·ACC 0001104659-26-077556·Filed Jun 25, 2026, 08:30 ET

NAME AND LIKENESS LICENSE AGREEMENT

Agassi Sports Entertainment Corp.

Filed by Avantafile.com - Agassi Sports Entertainment Corp. - Exhibit 10.1


NAME AND LIKENESS LICENSE AGREEMENT

 

This Name and Likeness License Agreement (this “Agreement”) is made to be effective as of June [●], 2026 (“Effective Date”), by and between AKA Licenses, LLC, a Nevada limited liability company (“AKA Licenses”), and Agassi Sports Entertainment Corp., a Nevada corporation (“AASP”). AKA Licenses and AASP shall be referred to herein collectively as the “Parties” and each may be referred to individually as a “Party.

 

RECITALS

 

WHEREAS, AKA Licenses is the holder of the right of publicity to the name, and related uses of the name, of Andre K. Agassi (the “Name”);

 

WHEREAS, Andre K. Agassi (“Agassi”) is a former professional tennis player and 8-time tennis Grand Slam winner, co-founder of AASP’s current business operations, and a significant stockholder of AASP;

EX-10.1·8-K·CIK 930245·ACC 0001472375-26-000179·Filed Jun 25, 2026, 08:30 ET

FORM OF LOCK-UP AGREEMENT

Agassi Sports Entertainment Corp.

Filed by Avantafile.com - Agassi Sports Entertainment Corp. - Exhibit 10.2


LOCK-UP AGREEMENT

This Lock-Up Agreement (this “Agreement”) is made and entered into as of May 27, 2026 between (i) Agassi Sports Entertainment Corp., a Nevada corporation (“Agassi Sports”), and (ii) the undersigned holder (the “Holder”) of common stock, $0.001 par value per share of the Agassi Sports (“Common Stock”). Agassi Sports and the Holder are sometimes referred to herein individually as a “Party” and, collectively, as the “Parties”.

 

WHEREAS, in November 2024, Agassi Sports entered into a series of subscription agreements, in connection with a private placement offering to certain accredited investors (the “Investors”), whereby Agassi Sports sold to 23 Investors, an aggregate of 2,631,543 shares of Common Stock for $0.95 per share of Common Stock, which offering closed on November 7, 2024 (the “2024 Offering”);

 

WHEREAS, the Holder was an Investor in the 2024 Offering;

EX-10.2·8-K·CIK 930245·ACC 0001472375-26-000179·Filed Jun 25, 2026, 08:30 ET